Prescribing patterns and therapeutic implications for diabetic hypertension in Bahrain

Annals of Pharmacotherapy

Volumn 35, Issue 11, 2001, Pages 1350-1359

  Al Khaja, K A J ^a   Sequeira, R P ^a   Mathur, V S ^a  

^a ARABIAN GULF UNIVERSITY   (Bahrain)

Author keywords

Diabetes mellitus; Hypertension

Indexed keywords

AMLODIPINE; ATENOLOL; BENZTHIAZIDE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CAPTOPRIL; CHLORTALIDONE; CLOPAMIDE; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; GLIBENCLAMIDE; GLICLAZIDE; HYDRAZINE; HYDROCHLOROTHIAZIDE; INDAPAMIDE; INSULIN; LISINOPRIL; METFORMIN; METHYLDOPA; METOPROLOL; NIFEDIPINE; PERINDOPRIL; PROPRANOLOL; RESERPINE; SULFONYLUREA; THIAZIDE DIURETIC AGENT; UNINDEXED DRUG; VERAPAMIL;

ADULT; AGED; ARTICLE; BAHRAIN; DRUG CHOICE; FEMALE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRACTICE GUIDELINE; PRESCRIPTION; PRIMARY HEALTH CARE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; WORLD HEALTH ORGANIZATION;

EID: 0034753934     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.10399     Document Type: Article

References (63)

1. Etiology and prevalence of hypertension in diabetic patients
2. Hypertension and associated metabolic abnormalities: The role of insulin resistance and sympathoadrenal system
3. Diabetes mellitus and hypertension
4. Long-term antihypertensive treatment inhibiting progression of diabetic nephropathy
5. Hypertension and diabetes
6. Comorbid conditions
7. Lipid and the progressive renal injury
8. Combination therapy for hypertension and renal disease in diabetics as compared to non-diabetics
9. Effects of intensive blood pressure lowering and low-dose aspirin in patients with hypertension
10. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38
11. 1999 World Health Organization/International Society of Hypertension guidelines for the management of hypertension
12. UKPDS 33: Intensive blood glucose control with sulfonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes
13. High prevalence of diabetes in Bahrainis: Association with ethnicity and raised plasma cholesterol
14. Antihypertensive drug utilization by primary care physicians in Bahrain
15. Patterns of utilization of antihypertensive drug combinations in Bahrain: Do they conform with international guidelines?
16. Drug-induced hypoglycemia: A review of 1418 cases
17. Oral hypoglycemic agents
18. Sulphonylureas and hypoglycemia
19. Use of antidiabetic and antihypertensive drugs in hospital and outpatient settings in Hong Kong
20. Obesity in Bahraini adults
21. Oral antidiabetic agents: A guide to selection
22. Pathophysiology of type 2 diabetes and modes of action of therapeutic interventions
23. National High Blood Pressure Education Program Working Group report on hypertension in diabetes
24. Statement on hypertension in diabetes mellitus. Final report
25. The fifth report of the Joint National Committee on detection, evaluation and treatment of high blood pressure (JNC V)
26. Insulin resistance compensatory hyperinsulinaemia: Role in hypertension, dyslipidaemia, and coronary heart disease
27. Management of hypertension and metabolic disorders
28. Drug treatment of hypertension complicating diabetes mellitus
29. Prevalence of arterial hypertension in diabetic patients before and after the JNC-V
30. Drug treatment: Present and future
31. Understanding the nature of renal disease progression
32. The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure
33. Guidelines for management of hypertension: Report of the third working party of the British Hypertension Society, 1999
34. Special considerations in the therapy of diabetic hypertension
35. Influence of long-term, low-dose, diuretic-based antihypertensive therapy on glucose, lipid, uric acid and potassium levels in older men and women with isolated systolic hypertension: The Systolic Hypertension in the Elderly Program
36. Diuretics and β-blockers do not have adverse effects at 1 year on plasma lipid and lipoprotein profiles in men with hypertension
37. Indapamide: A diuretic of choice for the treatment of hypertension?
38. Angiotensin-converting enzyme inhibitors: More different than alike? Focus on cardiac performance
39. Long-term evaluation of combined antihypertensive therapy with lisinopril and a thiazide diuretic in patients with essential hypertension
40. The use of captopril and captopril plus frusemide as antihypertensive agents in non-insulin dependent diabetes
41. Sexual symptoms in hypertensive patients: A clinical trial of antihypertensive medications
42. Essential hypertension
43. Diabetes and syndrome X: Focus on reduction of cardiovascular and renal events
44. Combination therapy in the treatment of hypertension
45. American Diabetes Association: Clinical practice recommendations 1997
46. ACE inhibitor-induced hypoglycemia
47. The effect of angiotensin-converting enzyme inhibition on diabetic nephropathy
48. Can we further slow down the progression to end-stage renal disease in diabetic hypertensive patients?
49. Outcome results of the Fosinopril versus Amlodipine Cardiovascular Events Randomized Trial (FACET) in patients with hypertension and NIDDM
50. The effect of nisoldipine as compared to enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension
51. Treating hypertension. Are the right drugs given to the right patients?
52. The classification of calcium antagonists and their selection in the treatment of hypertension
53. Effect of antihypertensive drugs on insulin, glucose and lipid metabolism
54. Effects of nifedipine on insulin secretion and plasma lipids in hypertensive patients
55. Comparison of the effects of atenolol and nifedipine on glucose, insulin, and lipid metabolism in patients with hypertension
56. The effects of verapamil, diltiazem, nifedipine and propranolol on metabolic control in hypertensives with non-insulin-dependent diabetes mellitus
57. Antihypertensive therapy and progression of diabetic renal disease
58. Calcium channel blockers versus other antihypertensive therapies on progression of NIDDM-associated nephropathy
59. Therapeutic efficacy of different antihypertensive drugs in human diabetic nephropathy: An update meta-analysis
60. Effects of cilazapril and amlodipine on kidney function in hypertensive NIDDM patients
61. Comparison of the renal effects of angiotensin-converting enzyme inhibitor and calcium antagonist in hypertensive type 2 (non-insulin-dependent) diabetic patients with microalbuminuria: A randomized controlled trial
62. Newer approaches to antihypertensive therapy: Use of fixed dose combination therapy
63. Effects of an ACE inhibitor/calcium antagonist combination on proteinuria in diabetic nephropathy